靶向 B 细胞成熟抗原的 CAR-T 细胞疗法 bb21217 治疗复发/难治性多发性骨髓瘤：I 期 CRB-402 研究结果

Chimeric antigen receptor (CAR) T-cell therapy enriched for a memory-like phenotype may persist and function longer than a nonenriched product, thereby improving duration of response (DOR).

We conducted a phase I study with bb21217 (NCT03274219), an anti-B-cell maturation antigen CAR T-cell therapy manufactured in the presence of the phosphoinositide 3-kinase inhibitor bb007 to enrich for T cells with a memory-like phenotype, in patients with relapsed/refractory multiple myeloma (N = 72). No new safety concerns were raised with bb21217 therapy (three cases each of grade 3 cytokine release syndrome and grade 3 neurotoxicity were observed). The objective response rate was 69. 4% and the median DOR was 23.

8 (95% confidence interval, 16. 8-34. 8) months. Analysis of the drug product established an association between early memory phenotype and robust expansion and depth of response. Examination of baseline characteristics indicated that tumor burden and prior therapies influenced DOR. The data indicate that generation of CAR T cells early in a disease course when tumor burden is lower and source material exhibits a more na ve phenotype may maximize the clinical benefit potential of the drug product.